CCL19 and neoplasm: Notably, mregDCs express CCL17, CCL19 and CCL22,26, 27 which promote Treg migration into the TME by binding to CCR4 and promoting tumour invasion and drug resistance to immune checkpoint blockade (ICB) treatment.53